Here's Why CRISPR Stocks Are Soaring Today
The results are in. Well, for the first two patients anyway.
Shares of the major gene editing stocks are soaring today after CRISPR Therapeutics (NASDAQ: CRSP) provided the first-ever clinical update for its lead drug candidate, CTX001, in transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD). Results from the first patient treated for each disease suggest that the gene-editing approach successfully altered red blood cells and may in fact live up to its curative potential.
The update pushed shares of CRISPR Therapeutics up as much as 26%, while shares of Editas Medicine (NASDAQ: EDIT) and Intellia Therapeutics (NASDAQ: NTLA) rose as much as 16.9% and 17.4%, respectively. The "rising tide lifts all boats" cliche applies here, but the daily gains for peers may be a bit generous, especially after considering the differences in approach.
Source Fool.com
